These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33270642)

  • 1. Adenovirus vectored IFN-α protects mice from lethal challenge of Chikungunya virus infection.
    Chen H; Min N; Ma L; Mok CK; Chu JJH
    PLoS Negl Trop Dis; 2020 Dec; 14(12):e0008910. PubMed ID: 33270642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection against Chikungunya virus induced arthralgia following prophylactic treatment with adenovirus vectored interferon (mDEF201).
    Dagley A; Ennis J; Turner JD; Rood KA; Van Wettere AJ; Gowen BB; Julander JG
    Antiviral Res; 2014 Aug; 108():1-9. PubMed ID: 24833276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy and long-term prophylaxis of vaccinia virus respiratory infections in mice with an adenovirus-vectored interferon alpha (mDEF201).
    Smee DF; Wong MH; Russell A; Ennis J; Turner JD
    PLoS One; 2011; 6(10):e26330. PubMed ID: 22022603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model.
    Kumaki Y; Ennis J; Rahbar R; Turner JD; Wandersee MK; Smith AJ; Bailey KW; Vest ZG; Madsen JR; Li JK; Barnard DL
    Antiviral Res; 2011 Jan; 89(1):75-82. PubMed ID: 21093489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single dose of an adenovirus vectored mouse interferon-α protects mice from lethal EV71 challenge.
    Sun J; Ennis J; Turner JD; Chu JJ
    Antiviral Res; 2016 Oct; 134():207-215. PubMed ID: 27623347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of nasal or pulmonary delivered treatments with an adenovirus vectored interferon (mDEF201) on respiratory and systemic infections in mice caused by cowpox and vaccinia viruses.
    Smee DF; Wong MH; Hurst BL; Ennis J; Turner JD
    PLoS One; 2013; 8(7):e68685. PubMed ID: 23874722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct Roles of Interferon Alpha and Beta in Controlling Chikungunya Virus Replication and Modulating Neutrophil-Mediated Inflammation.
    Cook LE; Locke MC; Young AR; Monte K; Hedberg ML; Shimak RM; Sheehan KCF; Veis DJ; Diamond MS; Lenschow DJ
    J Virol; 2019 Dec; 94(1):. PubMed ID: 31619554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon Alpha, but Not Interferon Beta, Acts Early To Control Chronic Chikungunya Virus Pathogenesis.
    Locke MC; Fox LE; Dunlap BF; Young AR; Monte K; Lenschow DJ
    J Virol; 2022 Jan; 96(1):e0114321. PubMed ID: 34668781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Single and Un-Adjuvanted Dose of a Chimpanzee Adenovirus-Vectored Vaccine against Chikungunya Virus Fully Protects Mice from Lethal Disease.
    Campos RK; Preciado-Llanes L; Azar SR; Lopez-Camacho C; Reyes-Sandoval A; Rossi SL
    Pathogens; 2019 Nov; 8(4):. PubMed ID: 31718104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction and Evaluation of Recombinant Adenovirus Candidate Vaccines for Chikungunya Virus.
    Cao L; Wang W; Sun W; Zhang J; Han J; Xie C; Ha Z; Xie Y; Zhang H; Jin N; Lu H
    Viruses; 2022 Aug; 14(8):. PubMed ID: 36016401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An adjuvanted adenovirus 5-based vaccine elicits neutralizing antibodies and protects mice against chikungunya virus-induced footpad swelling.
    Dora EG; Rossi SL; Weaver SC; Tucker SN; Mateo R
    Vaccine; 2019 May; 37(24):3146-3150. PubMed ID: 31047675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation of the N-Terminal Region of Chikungunya Virus Capsid Protein: Implications for Vaccine Design.
    Taylor A; Liu X; Zaid A; Goh LY; Hobson-Peters J; Hall RA; Merits A; Mahalingam S
    mBio; 2017 Feb; 8(1):. PubMed ID: 28223458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis.
    Lam S; Nyo M; Phuektes P; Yew CW; Tan YJ; Chu JJ
    MAbs; 2015; 7(6):1178-94. PubMed ID: 26305993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TLR3 mediated innate immune response in mice brain following infection with Chikungunya virus.
    Priya R; Patro IK; Parida MM
    Virus Res; 2014 Aug; 189():194-205. PubMed ID: 24905288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infectious Chikungunya Virus (CHIKV) with a Complete Capsid Deletion: a New Approach for a CHIKV Vaccine.
    Zhang YN; Deng CL; Li JQ; Li N; Zhang QY; Ye HQ; Yuan ZM; Zhang B
    J Virol; 2019 Aug; 93(15):. PubMed ID: 31092567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonism of the Sodium-Potassium ATPase Impairs Chikungunya Virus Infection.
    Ashbrook AW; Lentscher AJ; Zamora PF; Silva LA; May NA; Bauer JA; Morrison TE; Dermody TS
    mBio; 2016 May; 7(3):. PubMed ID: 27222471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus.
    Kumar M; Sudeep AB; Arankalle VA
    Vaccine; 2012 Sep; 30(43):6142-9. PubMed ID: 22884660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-17A Facilitates Chikungunya Virus Infection by Inhibiting IFN-α2 Expression.
    Neupane B; Acharya D; Nazneen F; Gonzalez-Fernandez G; Flynt AS; Bai F
    Front Immunol; 2020; 11():588382. PubMed ID: 33304351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A booster regime of liposome-delivered live-attenuated CHIKV vaccine RNA genome protects against chikungunya virus disease in mice.
    Rao S; Abeyratne E; Freitas JR; Yang C; Tharmarajah K; Mostafavi H; Liu X; Zaman M; Mahalingam S; Zaid A; Taylor A
    Vaccine; 2023 Jun; 41(27):3976-3988. PubMed ID: 37230889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon response factors 3 and 7 protect against Chikungunya virus hemorrhagic fever and shock.
    Rudd PA; Wilson J; Gardner J; Larcher T; Babarit C; Le TT; Anraku I; Kumagai Y; Loo YM; Gale M; Akira S; Khromykh AA; Suhrbier A
    J Virol; 2012 Sep; 86(18):9888-98. PubMed ID: 22761364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.